EQ insider trading
NasdaqCM HealthcareEquillium, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About Equillium, Inc.
Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need in the United States. Its lead product candidate is Itolizumab (EQ001), a first-in-class anti-CD6 immune-modifying monoclonal antibody, which is in phase 3 clinical trial to treat acute graft-versus-host disease, as well as completed Phase 1b clinical trial to treat systemic lupus erythematosus and lupus nephritis and in phase 2 clinical trial for the treatment of ulcerative colitis. The company also develops EQ101, first-in-class, selective, tri-specific inhibitor of IL-2, IL-9 and IL-15, which completed Phase 1/2 to treat cutaneous T cell lymphoma. It serves its products to gastroenterology, dermatology, hematology, transplant science, rheumatology, pulmonology, and oncology areas. The company has a collaboration and license agreement with Biocon SA to develop, make, have made, use, sell, have sold, offer for sale, import and otherwise exploit itolizumab (EQ001) and any pharmaceutical composition or preparation containing or comprising itolizumab (EQ001) that uses Biocon technology or Biocon know-how, or collectively, a Biocon Product. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.
Company website: www.equilliumbio.com
EQ insider activity at a glance
FilingIQ has scored 98 insider transactions for EQ since Oct 16, 2018. The most recent filing in our index is dated Mar 13, 2026.
Across the full history, 0 open-market purchases
and 45 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on EQ insider trades is 65.2/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest EQ Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
13F funds holding EQ
Frequently asked
- How many insider trades does FilingIQ track for EQ?
- FilingIQ tracks 98 Form 4 insider transactions for EQ (Equillium, Inc.), covering filings from Oct 16, 2018 onwards. 20 of those were filed in the last 90 days.
- Are EQ insiders net buyers or net sellers?
- Across the full Form 4 history for EQ, 0 transactions (0%) were open-market purchases and 45 (46%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does EQ insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is EQ in?
- Equillium, Inc. (EQ) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $116.92M.
Methodology & sources
Every EQ insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.